Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 7/20 | 0.50 |
| ▸ | CDK2 | P24941 | 7/20 | 0.50 |
| ▸ | CA2 | P00918 | 6/20 | 0.48 |
| ▸ | CA1 | P00915 | 5/20 | 0.48 |
| ▸ | CA9 | Q16790 | 3/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.47 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.47 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.47 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.47 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.47 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4908696 | 0.88 | NPC1 (0.52) | MEN1KMT2APOLBMAPTCCNA2 | |
| SCHEMBL14006462 | 0.86 | SCD (0.56) | MEN1KMT2AMAPTTNIK | |
| SCHEMBL4922841 | 0.84 | CHRM4 (0.56) | MEN1KMT2APOLBMAPTTNIK | |
| SCHEMBL14006470 | 0.82 | LCK (0.49) | MEN1KMT2AKDM4ETNIK | |
| SCHEMBL4918817 | 0.81 | LCK (0.46) | MEN1KMT2AMAPTKDM4ECCNA2 | |
| SCHEMBL4916854 | 0.80 | LCK (0.54) | MEN1KMT2APOLBMAPTKDM4E | |
| SCHEMBL4916678 | 0.79 | RXFP1 (0.52) | MEN1KMT2APOLBMAPTKDM4E | |
| SCHEMBL4919395 | 0.79 | SCD (0.57) | MEN1KMT2APOLBMAPTKDM4E | |
| SCHEMBL14034418 | 0.79 | LCK (0.46) | MEN1KMT2APOLBMAPTKDM4E | |
| SCHEMBL4919320 | 0.79 | EPM2A (0.48) | MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293785-A1 | SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-11-27 | — | — | US | claimed |
| WO-2007121154-A2 | SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | WO | claimed |
| US-20080293785-A1 | SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-11-27 | — | — | US | disclosed |
| US-20080293785-A1 | SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-11-27 | — | — | US | disclosed |
| US-20080293785-A1 | SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-11-27 | — | — | US | disclosed |
| WO-2007121154-A2 | SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007121154-A2 | SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293785-A1 | SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K2 | MEN1 3736/4885KMT2A 1541/4885POLB 3545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.